Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Shares Traded Last Trade
  -6.00 -0.67% 892.00 195,219 16:35:19
Bid Price Offer Price High Price Low Price Open Price
890.00 910.00 903.00 888.00 900.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.30 -9.72 -17.34 663
Last Trade Time Trade Type Trade Size Trade Price Currency
16:41:26 O 78,000 899.10 GBX

Maxcyte (MXCT) Latest News

More Maxcyte News
Maxcyte Investors    Maxcyte Takeover Rumours

Maxcyte (MXCT) Discussions and Chat

Maxcyte Forums and Chat

Date Time Title Posts
11/6/202111:01Maxcyte: Any molecule, any cell, any scale750
13/7/201614:43MaxCyte (MXCT) Right here, right now: catching the CAR-T wave2

Add a New Thread

Maxcyte (MXCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Maxcyte trades in real-time

Maxcyte (MXCT) Top Chat Posts

Maxcyte Daily Update: Maxcyte Inc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MXCT. The last closing price for Maxcyte was 898p.
Maxcyte Inc has a 4 week average price of 885p and a 12 week average price of 835p.
The 1 year high share price is 1,060p while the 1 year low share price is currently 180p.
There are currently 74,329,157 shares in issue and the average daily traded volume is 112,564 shares. The market capitalisation of Maxcyte Inc is £663,016,080.44.
gsbmba99: Judging by the sponsors and the people doing the voting, I wouldn't place any emphasis on a MediScience award. There are loads of these types of "awards" that are voted on by the media, financial PR and broker community. The awards are normally put on by an event company (eg "Ford Sinclair is a family-run event management company, with over 30 years' experience in delivering high profile live events"). The purpose of the "event" is to sell >£1,000 tables to the attendees. The shortlist is normally determined by the award sponsor and might well be focused on target or existing clients. The awards (particularly company of the year) often go to the companies and executives whose share prices increased the most in the recent past. I would be very surprised if the company submitted anything. But, the company (and its advisors) will now be contacted incessantly to encourage attendance at the event in November to eat rubbery chicken, drink overpriced wine, listen to 15 mins of a comedian du jour and, possibly, collect an award. It would be interesting to know if companies that don't pay to attend ever receive awards.
kenny: MXCT is a company capitalized at about £650m. All of that is hope value because: 1. MXCY has never made a profit and has accumulated losses of about $95m. 2. It finances itself by issuing new shares, annually. 3.The last balance sheet shows net assets of $33m. So, what is the hope value based upon. First that it obtains a Nasdaq listing which will maintain the share price at the crazy level it currently trades at – the greater fool theory. Second that it receives “milestoneR21; payments which if all those drugs proved successful is about $950m. However, it is stated that based upon past history, a third of the drugs may prove successful, so the realistic amount the company could receive is about $316m. Therefore, MXCT is capitalised at about three times its maximum potential earnings from its current portfolio, even when excluding its current annual operating expenses of $35m per annum. Investors seem to be confusing one-off milestone payments with repeating income. Admittedly, some years down the line there will be royalties on the medicines that prove to be successful but those royalties are far in the future. Also, are those royalties going to exceed its annual operating expenses? I think no one knows the answer. They seem to be good at public relations and selling their "story" of good times coming in the future, but will that rosy future transpire? Maybe this loss-making company will come good but even if it does, my view is that prodigious success is priced in already – and then some.
pogue: Facebook recovered though and went on to be a massive success as I said the UK would never value it. Why would someone who holds be negative on going to another market that specialises in new tech to maximise the share price? Your post is odd for a holder. As to not effecting a share sentiment drives shares I don't know where else you maybe posting the same point or if others are doing similar it maybe a coordinated set of posts any thing is possible but again it goes back to why post what is a negative on such obvious good news.
trident5: No they didn't - Facebook flopped on IPO and that was in the US. It's not a f deramp - how is my comment going to affect the share price? Grow up.
someuwin: ...Good article. Importantly, this isn't just another UK stock trying to artificially raise their share price by getting a Nasdaq listing. This IS a US company with US directors, premises and mojority US customers. The fact that they couldn't talk about the US listing with the recent results shows that things are moving fast in the background and they will announce listing initiation soon. Nasdaq listing will have a huge impact.
lomax99: Telegraph Questor today:Questor: a 'very special company' about to list where investors will be besotted with itQuestor share tip: MaxCyte offers huge potential but it may take a new listing on Nasdaq to get the share price higher stillWe can have no complaint about the performance of shares in MaxCyte, whose hi-tech machines help drugs firms make gene editing treatments: tipped at 370p in October last year, when we said they might be worth 500p, they closed last night at 886p and were as high as £10.40 in February.Normally we'd consider selling when a target price has been breached so comprehensively but MaxCyte finds itself in an anomalous position that it is about to rectify, a process that could do wonders for the share price.The company is based in America, has a roster of clients that are largely American and is the type of business that generates great enthusiasm among American investors – yet its shares trade on London's Aim market. It would make far more sense to have a listing on the stock market favoured by its natural investors – the Nasdaq in New York – and the company is in the process of getting just such a listing.In the words of Richard Penny of Crux Asset Management, which owns a stake in MaxCyte, "investors in the US are besotted with gene editing – they are hugely buoyant about what they see as the third age of drug discovery" built on the decoding of the human genome 20 years ago.Besotted investors are in much shorter supply here. Britain may have a huge fund management industry but when it comes to the healthcare sector it lacks the critical mass in terms of specialist analysts, funds and brokers found in America.In fact, you could say we are positively hostile to healthcare start-ups at present. "Fire sales of the small biotech firms held in Neil Woodford's funds depressed share prices and damaged sentiment across the board," Mr Penny said.We can be much more confident about a Nasdaq listing now than we were when we mentioned the possibility last year. When the firm announced in February the raising of £40m from seven new and existing investors (all but one of them American, unsurprisingly) it said: "The financing will strengthen the company's balance sheet as we continue to focus on accelerating revenue growth in 2021 and beyond, and marks a further important step towards our goal to dual-list on Nasdaq in 2021."But there are positive developments to report from the business's operations, too. Over the past year or so it has signed partnership agreements with four companies at the heart of what promises to be a whole new industry based on the "Crispr" gene editing tool, which won Nobel Prizes for chemistry for its inventors last year.The number of drugs being developed with the help of MaxCyte's "electroporation" machines has increased to more than 140, from about 100 at the time of our original tip, while the total in "milestones" the company could receive if all those drugs proved successful has risen from $800 (£578m) to "at least $950m".As we said before, not all of them will work but we can expect a success rate of perhaps a third. Meanwhile the company makes money by selling or leasing its machines, from the sale of consumables and, in a few years' time if all goes well, from royalties from successful treatments in which its technology was involved.Mr Penny acknowledged that "to some extent it requires the Nasdaq listing for the share price to remain high". But he added: "MaxCyte is a very special company. Maybe it's expensive for the London market but it's cheap for the US. The potential here is not just a rise of 10pc or 20pc. And at a market value of almost $1bn it is only just coming on some investors' radar." Questor says: holdTicker: MXCT
assagai: Surely there must be thousands of investors capable of joined up thinking. The potential for Maxcyte of the Crisper/Vertex is very significant so I have to ask , why is the share price on a continuous downward trend over the last couple of months. Depending on your "cup" the lack of mention of Nasdaq in the final results summation is troubling. No clue as to what came from the Analyst's briefing. Maybe time for a couple of probing questions to Brokers or maybe Maxcyte themselves. Time to fire up the Quattro!
thelongandtheshortandthetall: Incredibly stable share price today. Hmmmm.
someuwin: For those new to the story here, look at all these diseases that MXCT's tech is currently being used with in ongoing clinical trials. Each of these are being developed by, and funded by some of the biggest and best biotech companies in the world. MXCT calls them partners not customers. MXCT is getting revenues now for licenses, milestones, tech rental, sales etc. But as and when any of these drugs come to market MXCT will get significant royalties on sales. That's the BIG driver here - where else can you get exposure to that sort of upside at such a low price? And that's just the trials being done currently. We know that as they enter 2021 their pipeline of new partnerships is the largest they've ever seen!
gsbmba99: You are attributing the movement in the share price to the EDIT-301 presentation. I would argue share price movement is more likely to do with EDIT-201 (healthy donor NK cells) developments which was the subject of two presentations at ASH. See also recent performance of NKTX and FATE. I hope EDIT-301 does well but it's 2+ years behind CTX-001 and not obviously differentiated/better. Or it could be a relief rally of sorts following a flat performance YTD in a sector that's been performing very well. The good news is we'll never know. The use of MXCT technology in EDIT-301 was announced (via RNS) on 7 October 2019. "We look forward to working with MaxCyte and using its leading technology to develop EDIT-301 as a best-in-class medicine for the treatment of sickle cell disease and beta-thalassemia, and for up to four engineered cell medicines to treat cancer," said Charles Albright, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine.
Maxcyte share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210614 16:19:04